Key facts
- Notable investors include Creator Fund.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Immobilase
- ·The full record, as it builds
Funding rounds
No funding rounds for Immobilase are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Immobilase
Operator of an enzyme immobilization technology company intended to unleash the productive potential of enzymes by overcoming traditional constraints such as costs, single-use workflows and cold storage requirements. The company offers a novel immobilization method that delivers reusable, durable enzymes with room-temperature stability for over six months, enabling customers to significantly reduce costs, eliminate cold chain logistics and accelerate research and industrial applications in pharmaceuticals, cosmetics and food.
- Sector
- Healthcare
- HQ
- Morpeth, United Kingdom
- Founded
- 2025
- Website
- immobilase.com/
- Ownership
- Privately Held (backing)
Immobilase doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Immobilase shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Immobilase in its N-PORT filings yet. We sweep new filings monthly.